middle.news

Avecho Completes Treatment Phase in Phase III Insomnia Trial Ahead of June Interim Readout

10:00am on Thursday 1st of January, 1970 AEST Healthcare
Read Story

Avecho Completes Treatment Phase in Phase III Insomnia Trial Ahead of June Interim Readout

10:00am on Thursday 1st of January, 1970 AEST
Key Points
  • Treatment phase completed for 244 participants
  • Interim analysis results expected late June 2026
  • Trial supports TGA registration for OTC CBD insomnia treatment
  • Australian commercial rights licensed to Sandoz AG
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE